Effect of Hydroxychloroquine on Acute Respiratory Syndrome (Covid 19) and its Role on Blood Biomarkers Is Hydroxychloroquine Beneficial for Covid-19 Patients? |Biomedgrid

Background: Covid pandemic has challenged the world for a curable option. Hydroxychloroquine [HCQ], due to its immunologic and anti-inflammatory effect, has been tried during the initial pandemic but received a controversial benefit. Method: Cavan Monghan Hospital Group has performed a retrospective study of a total of 97 patients tested positive with Covid illness. The study aimed to measure the effect of hydroxychloroquine on respiratory system, certain inflammatory markers, and mortality risk. 49 patients received hydroxychloroquine and other 48 patients treated supportively. Result: The group of HCQ showed a reduction in the need of respiratory support and increase discharge rate. Also, mortality rate among critically ill patients has decreased, although the overall mortality among all patients showed no superiority of HCQ over the supportive care. Finally, HCQ demonstrated dramatic decrease of certain inflammatory markers. Conclusion: HCQ has shown a good anti-inflammatory property. Thus, we suggest this is the leading cause for earlier weaning of respiratory support and decrease hospital stay in comparison of other measure of standard care.